Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480104 | 0.79 | CES2 (0.37) | CES2NOTUM | |
| SCHEMBL6792041 | 0.77 | HSP90AA1 (0.36) | CES2 | |
| SCHEMBL29175684 | 0.77 | CYP3A4 (0.35) | CES2 | |
| SCHEMBL4018885 | 0.77 | CES2 (0.36) | CES2 | |
| SCHEMBL13388164 | 0.74 | ERN1 (0.32) | — | |
| SCHEMBL29589485 | 0.73 | CCR1 (0.34) | — | |
| SCHEMBL9772995 | 0.73 | CCR1 (0.34) | — | |
| SCHEMBL4016343 | 0.72 | TACR1 (0.36) | NOTUM | |
| SCHEMBL1186260 | 0.71 | NT5E (0.38) | CES2NOTUM | |
| SCHEMBL29956511 | 0.69 | HTR6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699569-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2699569-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8901145-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901145-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2012145617-A9 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2012145617-A2 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-8071778-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010148351-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2009096941-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-06 | — | — | WO | disclosed |
| CN-101495470-A | 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of CNS disorders | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2069328-A2 | 4-ARYLALKOXYMETHYL-4-PHENYL PIPERIDINES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | Brystol-Myers Squibb Company (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090030040-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-29 | — | — | US | disclosed |
| US-20080027056-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| WO-2008014247-A2 | 4 -ARYLALKOXYMETHYL-4- PHENYL PIPERIDINES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027056-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | CNR1, CNR2, PMP22 | CES2 41/4885NOTUM 2417/4885 |
| US-20120270892-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | CES2 4328/4885NOTUM 3716/4885 |
| US-20090030040-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | CES2 41/4885NOTUM 2417/4885 |
| US-20100331315-A1 | RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM2, PIM1, CDK2 | CES2 3640/4885NOTUM 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.